Ankylosing spondylitis

Disease ID:1196
Name:Ankylosing spondylitis
Associated with:0 target
14 immuno-relevant ligands
Synonyms
Bekhterev syndrome | Marie-Strumpell disease
Description
A bone inflammation disease that causes inflammation in the joints of the spine and pelvis.
Database Links
Disease Ontology: DOID:7147

Targets

No target related data available for Ankylosing spondylitis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
adalimumab
Immuno Disease Comments: Anti-TNFα monoclonal antibody therapy approved for ankylosing spondylitis.
Clinical Use: Used in the management of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis.
In 2015 both the EMA and the FDA approved the use of adalimumab as a treatment for hidradenitis suppurativa, a chronic skin disease that causes abscesses and scarring on the skin.
In July 2016, the FDA expanded adalimumab approval as the first non-corticosteroid drug available for use as a treatment for non-infectious intermediate, posterior and panuveitis (forms of autoimmune-driven inflammation of the uvea)- results from Phase 3 clinical trial NCT01138657 are published in [4]. | View clinical data
filgotinib
Immuno Disease Comments: A Phase 2 clinical candidate for ankylosing spondylitis (see NCT03117270).
Clinical Use: Filgotinib is in Phase II clinical trial for rheumatoid arthritis and Crohn's disease. Click here to link to ClinicalTrials.gov's complete listing of filgotinib Phase II trials. | View clinical data
etoricoxib
Immuno Disease Comments: Selective COX2 inhibitor approved for the treatment of many inflammatory conditions including ankylosing spondylitis.
Clinical Use: Used in the treatment of rheumatoid arthritis, osteoarthritis, chronic lower back pain, ankylosing spondylitis, acute pain and gout. There is no information regarding approval for medicinal use of etoricoxib on the US FDA website. Individual national agencies may have granted marketing approval. | View clinical data
flurbiprofen
Immuno Disease Comments: Approved NSAID used for many inflammatory conditions including ankylosing spondylitis.
Clinical Use: Flurbiprofen is approved to treat the pain and inflammation associated with rheumatic diseases and other musculoskeletal disorders, as well as dysmenorrhoea, migraine and as postoperative analgesia. | View clinical data
IL-17A
Immuno Disease Comments: Approved therapy for systemic ankylosing spondylitis.
naproxen
Immuno Disease Comments: Approved NSAID used for ankylosing spondylitis.
Clinical Use: Used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and acute gout. Also used in pain relief in the treatment of primary dysmenorrhea. | View clinical data
sulindac
Immuno Disease Comments: Approved drug for ankylosing spondylitis.
Clinical Use: For acute relief or long term use in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder and acute gouty arthritis. | View clinical data
Bioactivity Comments: We have been unable to find affinity data for this drug to substantiate its MMOA | View biological activity
golimumab
Immuno Disease Comments: An anti-TNFα therapy approved for ankylosing spondylitis.
Clinical Use: Used in adults with various inflammatory conditions [9] e.g. moderate to severe active rheumatoid arthritis [5], active psoriatic arthritis, active ankylosing spondylitis and moderate to severe ulcerative colitis. | View clinical data
etanercept
Immuno Disease Comments: Approved drug for AS.
Clinical Use: Used to treat severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis. | View clinical data
sarilumab
Immuno Disease Comments: Clinical trial in ankylosing spondylitis was terminated.
Clinical Use: Sarilumab was granted FDA approval as a treatment for moderate to severe active RA in May 2017 (with EMA approval granted in June 2017), following evaluation in several clinical trials, either as a monotherapy (eg NCT02121210) or in combination with other drugs such as , , and .
Click here to link to ClinicalTrials.gov's listing of Phase III sarilumab trials. A Phase II study for non-infectious uveitis (NCT01900431) has been completed, whereas a Phase II extension study (NCT01118728) for ankylosing spondylitis was terminated. | View clinical data
secukinumab
Immuno Disease Comments: Approved therapeutic for ankylosing spondylitis.
Clinical Use: Secukinumab is approved by the US FDA for the treatment of plaque psoriasis.
Secukinumab also met its clinical endpoints in Phase III clinical trial for ankylosing spondylitis (NCT01649375) [1], and was FDA approved for this indication and psoriatic arthritis [7-8] in January 2016.
The antibody is also in Phase II clinical trial for multiple sclerosis (NCT01874340) based on results from experiments in an animal model of the disease (experimental autoimmune encephalomyelitis, EAE) and in vitro human cell assays [3]. | View clinical data
risankizumab
Immuno Disease Comments: Phase 2 proof of concept trial in ankylosing spondylitis has been completed.
Clinical Use: Risankizumab has reached Phase II clinical trial for Crohn's disease (CD), psoriasis, and ankylosing spondylitis (AS). Results from the first-in-human proof-of-concept trial in patients with psoriasis are reported in [6]. | View clinical data
MRL-367
Immuno Disease Comments: Experimental compound with predicted application in ankylosing spondylitis.
Bioactivity Comments: In a RORγ/Gal4 cell-based reporter assay MRL-367 inhibits RORγt with an IC50 of 41nM, and shows no significant activity against a panel of related nuclear hormone receptors [2]. | View biological activity
MRL-248
Immuno Disease Comments: Experimental compound with predicted application in ankylosing spondylitis.
Bioactivity Comments: In a RORγ/Gal4 cell-based reporter assay MRL-248 inhibits RORγt with an IC50 of 118nM, and shows no significant activity against a panel of related nuclear hormone receptors [2]. | View biological activity

References

Show »

1. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M et al.. (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal od Medicine, 373 (26): 2534-2548.

2. de Wit J, Al-Mossawi MH, Hühn MH, Arancibia-Cárcamo CV, Doig K, Kendrick B, Gundle R, Taylor P, Mcclanahan T, Murphy E et al.. (2016) RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. J. Allergy Clin. Immunol., 137 (3): 960-3. [PMID:26611672]

3. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. (2014) The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia, 62 (5): 725-35. [PMID:24677511]

4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al.. (2016) Adalimumab in Patients with Active Noninfectious Uveitis. N. Engl. J. Med., 375 (10): 932-43. [PMID:27602665]

5. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z et al.. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum., 58 (4): 964-75. [PMID:18383539]

6. Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D et al.. (2015) Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol., 136 (1): 116-124.e7. [PMID:25769911]

7. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB et al.. (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 386 (9999): 1137-46. [PMID:26135703]

8. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J et al.. (2015) Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N. Engl. J. Med., 373 (14): 1329-39. [PMID:26422723]

9. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ et al.. (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol, 47 (3): 383-96. [PMID:17322150]